tbuckley/cabot-search huggingface dataset:
Prognostic Impact of Incidental Hepatocellular Carcinoma after Liver Transplantation
Authors: M. Rodríguez-Perálvarez, P. Pérez, L. Guerrero, V. González, R. Sánchez, M. Centeno, A. Poyato, P. Barrera, R. Ciria, J. Briceño, J.L. Montero, M. De la Mata
Journal: Journal of Hepatology (2016)
The Oral PKC-β Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway.
Authors: Antonino Neri, Sandra Marmiroli, Pierfrancesco Tassone, Luigia Lombardi, Lucia Nobili, Donata Verdelli, Monica Civallero, Maria Cosenza, Jessika Bertacchini, Massimo Federico, Anto De Pol, Giorgio Lambertenghi Deliliers, Stefano Sacchi
Journal: Blood (2006)
Use of functional protein pathway activation mapping in glioblastoma samples to differentiate long-term from short-term survivors along with pathway-driven molecular subgroups.
Authors: C. Mueller, H. Fillmore, W. Broaddus, J. C. Watson, R. H. Lipsky, M. Cremona, J. Deng, L. A. Liotta, J. D. Wulfkuhle, E. Petricoin
Journal: Journal of Clinical Oncology (2010)

2051 Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. It is highly lethal, with a median survival time of 9 to 18 months. New prognostic biomarkers are critically needed to help predict survival and to identify potential targets for therapy of prognostic subgroups. While GBM has recently been characterized by genomic analysis, little is known about what protein pathways are activated in GBM that could be useful for stratification to targeted therapeutics. We have applied a novel protein pathway activation mapping technique to study a set of GBM samples to identify signaling pathways that correlate with survival, and generate a new basis for molecular classification of GBM based on signaling portraits. Methods: Tumor cells from 44 frozen resection samples of GBM patients, were isolated using Laser Capture Microdissection. The activation (phosphorylation) status of over 100 key signaling proteins was then quantitatively measured in these samples by Reverse Phase Protein Microarray. Patients were treated by surgery and external beam radiation therapy, followed by chemotherapy. Statistical analysis of short term survivors (N=21, median OS 4 months) and long term survivors (n = 20, median OS 21 months) was performed using Wilcoxon rank sum and Kaplan Meier analysis. Results: Analysis revealed differently activated proteins that could discriminate short-term and long-term survivors (p < 0.05) that are involved in angiogenesis (VEGFR2, eNOS, HIF1 alpha), cytoskeleton and cytoskeleton reorganization (adducin, beta actin, PAK1/2), apoptosis (bcl-2, caspase 3), growth factor signaling (cKIT, IGFR, IRS) as well as centrally important downstream cytoplasmic kinases (AKT, PKC alpha, FAK, PLK1). Conclusions: Network-scale protein signaling activation analysis of GBM samples identified a novel prognostic signature comprised of phosphoproteins whose activation correlated with OS. These results, if validated in a larger study set, could form the basis of personalized therapy trials for GBM where pathway signatures are used to rationally stratify and select patients for molecular targeted inhibitors. No significant financial relationships to disclose.
B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial
Authors: Ruth Mary de Tute, Sharon Barrans, Andy C. Rawstron, Christopher T Manbridge, Josh Caddy, Keith Pugh, Peter W.M. Johnson, Andrew J Davies, Andrew Jack
Journal: Blood (2015)
Distinct Cell-Specific TNFR1-Signaling Determines Liver Damage in Experimental Hepatitis
Authors: R. Wroblewski, M. Armaka, V. Kondylis, M. Pasparakis, A.W. Lohse, J.S. zur Wiesch, G. Kollias, H. Ehlken
Journal: Journal of Hepatology (2016)
Low frequency of antibodies against citrullinated vimentin (MCV) and rheumatoid factor (RF) in unaffected members of multi-case families with rheumatoid arthritis (RA) from Northern Sweden
Authors: L. Arlestig, H. Kokkonen, E. Einarsdottir, Solbritt Rantapää Dahlqvist
Journal: Annals of the Rheumatic Diseases (2007)

Low frequency of antibodies against citrullinated vimentin (MCV) and rheumatoid factor (RF) in unaffected members of multi-case families with rheumatoid arthritis (RA) from Northern Sweden
HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity
Authors: A. Lampis, L. Cascione, R. Burke, P. Clarke, M. Simbolo, A. Scarpa, E. Bosma, S. Yu, R. Cole, M. Stubbs, S. Sharp, R. van Montfort, J. Hahne, M. Fassan, P. Workman, N. Valeri, C. Braconi
Journal: Journal of Hepatology (2016)
The Role of Alemtuzumab Compared to Antitymocyte Globulin in Non-Myeloablative Stem Cell Transplantation; Especially for the Prevention of GVHD and Immune Recovery.
Authors: In Hae Park, June-Won Cheong, Jee Young Lee, Jin Seok Kim, Hyun Ju Chun, Yuri Kim, Sun Young Park, Jin Koo Lee, Yoo-Hong Min
Journal: Blood (2005)
A Systematic Literature Review of the Epidemiology and Economic Burden Associated with Non-Alcoholic Steatohepatitis
Authors: A.J. Sanyal, A.L. Martin, S.M. Cadarette, M.D. Burns, D. Guranlioglu, B. Kartman, K.M. Henriksson, M.B. Hansen
Journal: Journal of Hepatology (2016)
Tyrosine Kinase FLT3 and C-KIT Receptor Expression in Patients with Myelodysplastic Syndromes – A Preliminary Study
Authors: Emília Cortesão, Ana Cristina Goncalves, Isabel Sousa, Carlos Moucho, Luís Carlos Rito, Emília Magalhaes, José Pedro Carda, Catarina Geraldes, Patrícia Sousa, Nuno Costa e Silva, Ana Espadana, Amélia Pereira, Adriana Teixeira, Graça Ribeiro, José Nascimento Costa, Ana Bela Sarmento Ribeiro
Journal: Blood (2012)
Serum Levels of Wisteria Floribunda Agglutinin-Positive MAC-2 Binding Protein as Short-Term Predictors of Hepatocellular Carcinoma in Chronic Hepatitis B
Authors: J. Liu, H.-H. Hu, H.-I. Yang, M. Korenaga, M.-H. Lee, C.-L. Jen, R. Batrla-Utermann, S.-N. Lu, L.-Y. Wang, S.-L. You, M. Mizokami, C.-J. Chen
Journal: Journal of Hepatology (2016)
Irreversible Modification of Circulating Albumin in Acute on Chronic Liver Failure (ACLF) Triggers Neutrophil Burst via Inducing Genes Associated to Cytokine Release and Cellular Stress
Authors: S. Das, J.S. Maras, S. Hussain, P. David, S.M. Shasthry, N. Trehanpati, S.K. Sharma, T.P. Singh, S.K. Sarin
Journal: Journal of Hepatology (2016)
The FTO rs1421085 T &gt; C Polymorphism is Associated with the Severity of Non-Alcoholic Fatty Liver
Authors: M.T.A. Loste, R. Gallego-Duran, C. Alonso, P. Iruzubieta, J. Ampuero, D. Ramos, A. Gil-Gomez, J. Abad, E. Fábrega, J.L. Calleja, R.J. Andrade, C. García-Monzón, M. Romero-Gomez, J. Crespo
Journal: Journal of Hepatology (2016)
Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma
Authors: Ruifen Dong, Wenan Qiang, Haiyang Guo, Xiaofei Xu, J. Julie Kim, Andrew Mazar, Beihua Kong, Jian-Jun Wei
Journal: Journal of Hematology & Oncology (2016)

Patient derived xenografts (PDX) are generated by transplanting the original patient's tumor tissue into immune-deficient mice. Unlike xenograft models derived from cell lines, PDX models can better preserve the histopathology from the original patient and molecular pathways. High-grade serous carcinoma (HGSC) is a deadly form of ovarian/fallopian tube cancer whose response to current chemotherapies varies widely due to patient variability. Therefore, a PDX model can provide a valuable tool to study and test treatment options for each individual patient.In this study, over 200 PDX tumors from nine HGSC were analyzed to investigate the nature and behavior of PDX tumors originating from HGSC. PDX tumors were serially passaged (from P0 to P4) and tumors were grafted orthotopically under the ovarian bursa or subcutaneously.Comparative analysis of the histology and molecular markers of tumors from over 200 PDX tumor-bearing mice, revealed that the tumors maintained similar histologies, stem cell populations, and expression for the majority of the tested oncogenic markers, compared to the primary tumors. However, a significant loss of steroid hormone receptors and altered expression of immunoresponsive genes in PDX tumors were also noted.Our findings provide substantial new information about PDX tumor characteristics from HGSC which will be valuable towards the development of personalized therapy and new drug development for HGSC.
Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Genotype 1, after Liver Transplantation: Efficacy and Safety
Authors: G.S. Antolin, M. Testillano, M. Prieto, I. Fernandez, X. Xiol, M.C. Londoño, L. Castells, J.M. Pascasio, M.L.G. Dieguez, A.O. Ferreiro, M. Salcedo, I. Narvaez, J.A. Pons, J.I. Herrero, S.P. Bartolome, J.L. Montero, A. Arencibia, E.F. Garcia, S. Lorente, E. Molina, J.R. Fernandez, C.A. Alvarez, V. Cuervas-Mons
Journal: Journal of Hepatology (2016)
High SVR Rates with SMV + SOF in HCV GT1 and GT4 Patients with Cirrhosis or Advanced Fibrosis: A Real Practice Analysis from a Large Regional Database in Tuscany, Italy
Authors: E. Salomoni, E. Gianni, L. Gragnani, F. Oliveri, M.R. Brunetto, S. Luchi, D. Bartolozz, P. Forte, S. Sani, P. Blanc, R. Sacco, A.L. Zignego, A. De Luca, D. Tacconi, D. Aquilini, F. Menichetti, C. Catalani, C. Nencioni, P. Carrai, S. Chigiotti, P. Colombatto
Journal: Journal of Hepatology (2016)
Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis
Authors: Robin M. Murray, Harriet Quigley, Diego Quattrone, Amir Englund, Marta Di Forti
Journal: World Psychiatry (2016)

Epidemiological evidence demonstrates that cannabis use is associated with an increased risk of psychotic outcomes, and confirms a dose-response relationship between the level of use and the risk of later psychosis. High-potency cannabis and synthetic cannabinoids carry the greatest risk. Experimental administration of tetrahydrocannabinol, the active ingredient of cannabis, induces transient psychosis in normal subjects, but this effect can be ameliorated by co-administration of cannabidiol. This latter is a constituent of traditional hashish, but is largely absent from modern high-potency forms of cannabis. Argument continues over the extent to which genetic predisposition is correlated to, or interacts with, cannabis use, and what proportion of psychosis could be prevented by minimizing heavy use. As yet, there is not convincing evidence that cannabis use increases risk of other psychiatric disorders, but there are no such doubts concerning its detrimental effect on cognitive function. All of the negative aspects are magnified if use starts in early adolescence. Irrespective of whether use of cannabis is decriminalized or legalized, the evidence that it is a component cause of psychosis is now sufficient for public health messages outlining the risk, especially of regular use of high-potency cannabis and synthetic cannabinoids.
Identification of Molecular Targets of AML by Phosphoproteomic Screening of Valproic Acid Treated BNML and C. Elegans RNAi Validation.
Authors: Rakel Brendsdal Forthun, Emmet McCormack, Tanima Sengupta, Siv Lise Bedringaas, Øystein Bruserud, Gry Sjøholt, Hilde Nilsen, Bjorn Gjertsen
Journal: Blood (2009)
Elevated Mean Platelet Volume Improves Current Non-Invasive Markers of Fibrosis and Predicts Acute Cardiovascular Events in Non-Alcoholic Fatty Liver Disease Patients
Authors: M. Adler, P. Manousou, I. Rishi, S. Atkinson, M. Yee, S. Khan, J. Lloyd, R. Goldin, M. Thursz
Journal: Journal of Hepatology (2016)
International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.
Authors: Franck Bonnetain, Adelaide Doussau, Simone Mathoulin-Pelissier, Bert A Bonsing, Bengt Glimelius, Karin Haustermans, Thierry Conroy, Jean-Luc Van Laethem, Roberto Labianca, Teresa Macarulla, Murielle E. Mauer, Manfred P. Lutz, Josep Tabernero, Aimery De Gramont, Pascal Hammel, Daniela Ellen Aust, Michel Ducreux, Julien Taïeb, John P. Neoptolemos, Laurence Collette
Journal: Journal of Clinical Oncology (2012)

4053 Background: Variability in the definition of survival endpoints in oncology trials was identified (Mathoulin et al.JCO 2008). Lack of a formal consensus could cause this, which limits inter-trial comparisons. The DATECAN project aimed at obtaining a formal consensus recommendation for defining survival endpoints for randomized clinical trials (RCTs) in the following cancer sites: pancreas, sarcoma/GISTs, breast, colorectal, gastric/œsophagus, head and neck, kidney-bladder. We report results for pancreatic cancer. Methods: Based on a literature review of RCTs (2006-2009), we identified survival endpoints and events currently used. A 2-round modified Delphi method using RAND scoring (range:1-9) was used to reach consensus. Academic research groups were contacted for participation in order to select clinicians and methodologists for Pilot and Scoring groups (&gt;30 experts/localization). Results: The Pilot group identified 14 endpoints that needed definition through consensus, such as progression free survival (PFS), time-to-treatment failure, time to quality of life deterioration. Endpoint definitions were seeked by disease setting (detectable disease vs not). Amongst the 52 European experts contacted, 33 and 30 participated to the 1 st and 2 nd round respectively. The experts scored a total of 204 events; a consensus was reached for 25 (12%) at the 1 st round and 156 (76%) at the 2 nd round. As example PFS was defined as time interval between the date of randomization, and the day of first local, regional progression or occurrence of distant metastases (including liver or non liver metastases) or occurrence of 2 nd pancreatic cancer or death (all causes), whichever occurs first. The consensus was finalized during a face-to-face meeting organized during the ESMO 2011 congress and general rules were proposed for final ratification. Conclusions: Based on this consensus, an European charter is being finalized and proposed for endorsement to all academic groups in order to harmonize results and to allow formal comparisons of pancreatic RCTs. The impact of these definitions on trial results will be also investigated in a further project.
Overcoming Graft Rejection in Adult Patients with High-Risk Severe Aplastic Anemia Using Supplemental CD34+-Enriched PBSC in Combination with BM.
Authors: Byung-Sik Cho, Sung-Yong Kim, Yoo-Jin Kim, Ki-Seong Eom, Hee-Je Kim, Seok Lee, Chang-Ki Min, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim
Journal: Blood (2007)
Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice
Authors: J. Cabezas, M.C. Londoño, S. Llerena, R. Muñoz, C. Baliellas, M. Buti, J.M. Pascasio, F. Saez-Royuela, J. García-Samaniego, J. de la Vega, P. Sanchez-Pobre, C. Alvarez-Navascues, J.A. Carrión, F. Gea, R.M. Morillas, M. Fernandez-Bermejo, A. Castro, M. Rivero, J.R. Fernandez, M. Berenguer, J.J. Moreno, D. Rincon, J.L. Calleja, J. Crespo
Journal: Journal of Hepatology (2016)
Postdischarge Suicides
Authors: Merete Nordentoft, Annette Erlangsen, Trine Madsen
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin for 12 Weeks in Subjects with Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Galaxy Study
Authors: J.G. O’Leary, K. Brown, J. Burton, R. Firpi-Morell, R.J. Fontana, A. Muir, C. O’Brien, M. Rabinovitz, K. Rajender Reddy, R. Ryan, A. Shprecher, S. Villadiego, A. Prabhakar, R.S. Brown
Journal: Journal of Hepatology (2016)
Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy
Authors: N. M. Kuderer, J. Crawford, D. C. Dale, G. H. Lyman
Journal: Journal of Clinical Oncology (2005)

8117 Introduction: Randomized controlled trials (RCTs) of prophylactic G-CSF have demonstrated a significant reduction in the incidence of febrile neutropenia (FN) in cancer patients receiving systemic chemotherapy. Methods: A comprehensive search for all reported RCTs of prophylactic G-CSF in non-myeloid malignancies was undertaken using electronic databases and hand searching of published references. Following assessment for heterogeneity, summary estimates of relative risk (RR [95% CL]) were estimated based on the Mantel-Haenszel method utilizing a random effects model. Results: Fourteen RCTs from 13 reports were identified including 3091 patients (Control: 1544; G-CSF: 1547). Disease categories included: lymphoma (n=6) and solid tumors (n=8). G-CSF consisted of filgrastim (n=10), lenograstim (n=3) or pegfilgrastim (n=1). FN was reported in 892 patients including 576 controls (37.3%, range 7–77%) and 316 receiving G-CSF (20.4%, range 0–63%) (RR=0.54 [.43, .69]; P<.0001). Subgroup estimates for FN include: lymphoma (RR=.69 [.58, .82]; P<.001), solid tumors (RR=.45 [.30, .68]; P<.001), elderly only (RR=.65 [.54, .79]; P<.001), placebo controlled studies (RR=.49 [.43, .69]; P<.001), filgrastim (RR=.58 [.51, .67]; P<.001), lenograstim (RR=.78 [.63, .98]; P=.032), pegylated filgrastim (RR=.08 [.03, .18]; P<.001). Infection-related mortality (IRM) was reported in 10 studies (2483 patients). IRM was observed in 55 controls (4.4%, range 0–14%) and 30 with G-CSF (2.4%, range 0–7%) (RR=.55 [.36, .84]; P=.005). IRM subgroup estimates include: lymphoma (RR=.58 [.33, 1.03]; P=.068), solid tumors (RR=.47 [.24, .92]; P=.032), elderly only (RR=.51 [.27, .97]; P=.045), filgrastim (RR=.51 [.32, .82]; P=.006), lenograstim (RR=1.00 [.25, 4.06]; P=.997), pegylated filgrastim (RR=.26 [.03, 2.54]; P=.300). Dose intensity was reported in 8 trials (1574 patients) averaging 88.1% [85.6, 90.2] in controls and 94.5% [92.6, 95.9] in G-CSF patients (P<.001). Disease-free and overall survival was not assessed in most studies. Conclusions: Prophylactic G-CSF significantly reduces the incidence of FN and infection-related mortality and increases delivered dose intensity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen
Hyper-Recovery Of Platelet After Induction Therapy Is a Significant Predictor For Relapse In Acute Myeloid Leukemia
Authors: Etsuko Yamazaki, Megumi Itabashi, Ogusa Eriko, Ayumi Numata, Wataru Yamamoto, Satomi Ito, Takuya Miyazaki, Takayoshi Tachibana, Hideyuki Kuwabara, Maki Hagihara, Kenji Matsumoto, Hideyuki Koharazawa, Jun Taguchi, Naoto Tomita, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Koji Ogawa, Yoshiaki Ishigatsubo
Journal: Blood (2013)
Retrospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment with Trientine in Wilson Disease Patients Withdrawn from Therapy with D-Penicillamine
Authors: K.-H. Weiss, A. Albillos, R. Bruha, L. Demelia, A. Dhawan, W. Griffiths, G. Hirschfield, R. Houwen, N. Manolaki, A. Poujois, C. Ribes, G.C. Sturniolo, M. Zuin, S. Chowdhury, P. Ferenci
Journal: Journal of Hepatology (2016)
Direct Antiviral Combination Treatment According to Presence of Baseline Ravs in NS3, NS5A and NS5B Leads to High SVR Rates in Non-Cirrhotic and Cirrhotic Genotype 1 Infected Patients
Authors: K.-H. Peiffer, S. Susser, J. Dietz, C. Berkowski, D. Perner, S. Passmann, M. Raeder, J. Vermehren, C. Lange, S. Klein, N. Weiler, S. Zeuzem, C. Sarrazin
Journal: Journal of Hepatology (2016)
Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade
Authors: J.-F. Blanc, S.L. Chan, J.O. Park, B.-Y. Ryoo, C.-J. Yen, M. Kudo, R. Poon, D. Pastorelli, A. Baron, T.F. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I. Chau, P. Abada, S.-C. Chang, L. Yang, A. Zhu
Journal: Journal of Hepatology (2016)
Use of Non-Selective Beta Blockers (NSBB) in Cirrhotic Patients with Bacterial Infections is Associated with Lower Frequency of Sepsis, but not of Acute-On-Chronic Liver Failure (ACLF) or Survival. Results of a Prospective Study
Authors: G.H. Pereira, C. Baldin, L. Victor, J. Piedade, L. Guimarães, T. Rocha, Z. Veiga, F. Fernandes, E. Ahmed, J.L. Pereira
Journal: Journal of Hepatology (2016)
Abstract P280: Changes in Food Prices Improve Cardiovascular Disease (CVD) Outcomes
Authors: Stephen Sy, Jose Peñalvo, Shafika Abrahams-Gessel, Sartaj Alam, Ankur Pandya, Dariush Mozaffarian, Thomas A Gaziano
Journal: Circulation (2016)

Introduction: Changes in food prices can lead to healthier dietary patterns. Recent meta-analyses suggest the responses differ by food category with respect to impact on disease outcome. Hypothesis: We tested the hypothesis that a 10% subsidy on price of fruits, vegetables and whole grains, and a 10% tax on sugar-sweetened beverages, would have differential effects on CVD mortality, non-fatal MI and stroke, and diabetes over a 5-year period through a 20-year period in the U.S. Methods: We used an individual-based microsimulation CVD risk prediction model of a million adults created from NHANES sample (aged 35+). Model inputs included patient risk factor information, CVD risk equations, and intervention effectiveness data. The baseline cohort was expanded by adding additional groups of 35-year olds annually to produce cross-sectional outcomes from 2015-2035. Results: Using a conservative estimate of population growth, we project that the subsidy-increased consumption of fruits and vegetables would lead to 5- and 20-year reductions of CVD deaths by 8% and 10%, reductions in non-fatal MI by 16% and 18%, and reductions in non-fatal stroke by 25% and 24%, respectively. Subsidy-increased whole grain consumption would have corresponding reductions of 2.5% and 3% for CVD deaths and 9.1% and 9.7% for MI (Table). Tax-induced decreased consumption of sugar sweetened beverages would reduce 5- and 20-year CVD deaths by 0.8% and 1.3%, MI by 2.5% and 2.5%, stroke by 1.8% and 2.3%, and diabetes by 2.6% and 9.8%. Combined these numbers translate to prevention of over 3.5 million CVD deaths and over 4 million combined CVD events by 2035, assuming independent benefits for each food group. Conclusions: Pricing interventions resulting in differential changes in dietary habits can significantly reduce CVD outcomes in the U.S by different amounts. Further research should be done in assessing the cost-effectiveness of applying these price changes, as well as the compliance of the population to maintain healthy dietary habits over the 20-year horizon.
Cd362+ Human Mesenchymal Stromal Cells Reduce Hepatic Inflammation and Induce M2 Macrophage Polarisation in Murine Models of Primary Sclerosing Cholangitis
Authors: V. Vigneswara, M. Alfaifi, D. Hedegaard, D. Haldar, Y. Chen, M. Gargesha, A. Owen, S. Siew, C. Baan, A. Viola, D. Roy, M. Hoogduijn, S. Elliman, G.M. Hirschfield, P.N. Newsome
Journal: Journal of Hepatology (2016)